[HTML][HTML] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers, S Arora… - Annals of …, 2017 - Elsevier
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers… - Annals of …, 2017 - portal.findresearcher.sdu.dk
Background: Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention ofchemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention ofchemotherapy-induced nausea and vomiting in …
[PDF][PDF] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers, S Arora… - Annals of …, 2017 - core.ac.uk
Background: Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
[PDF][PDF] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang… - Annals of …, 2017 - findresearchersdu.elsevierpure.com
Background: Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention ofchemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention ofchemotherapy-induced nausea and vomiting in …
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers… - Annals of …, 2017 - annalsofoncology.org
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.
S Barbour, T Smit, X Wang, D Powers… - Annals of Oncology …, 2017 - europepmc.org
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang… - Annals of oncology …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
[HTML][HTML] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang, D Powers, S Arora… - Annals of …, 2017 - ncbi.nlm.nih.gov
Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
[PDF][PDF] Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
S Barbour, T Smit, X Wang… - Annals of …, 2017 - findresearchersdu.elsevierpure.com
Background: Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …